Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2018 |
| Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/30412 |
Resumo: | 2019-12-08 |
| id |
CRUZ_aa556eb36ef213c367e8369cb12a883e |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/30412 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Landovitz, Raphael JLi, SueGrinsztejn, BeatrizDawood, HalimaLiu, Albert YMagnus, ManyaHosseinipour, Mina CPanchia, RavindreCottle, LeslieChau, GordonRichardson, PaulMarzinke, Mark AHendrix, Craig WEshleman, Susan HZhang, YinfengTolley, ElizabethSugarman, JeremyKofron, RyanAdeyeye, AdeolaBurns, DavidRinehart, Alex RMargolis, DavidSpreen, William RCohen, Myron SMcCauley, MarybethEron, Joseph J2018-12-05T18:04:24Z2018-12-05T18:04:24Z2018LANDOVITZ, R. J. et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS medicine, v. 15, n. 11, p. e1002690, 2018.1549-1277https://www.arca.fiocruz.br/handle/icict/3041210.1371/journal.pmed.1002690engPublic Library of ScienceSafety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trialinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article2019-12-08UCLA Center for Clinical AIDS Research and Education. Los Angeles, California, United States of America.Statistical Center for HIV/AIDS Research and Prevention. Fred Hutchinson Cancer Research Center. Seattle, Washington, United States of America.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.University of KwaZulu Natal. Centre for the AIDS Programme of Research in South Africa. Durban, South Africa.Bridge HIV. Population Health Division. San Francisco Department of Health. San Francisco, California, United States of America.George Washington University. Milken Institute School of Public Health. Department of Epidemiology and Biostatistics. Washington, District of Columbia, United States of America.UNC Project-Malawi. Lilongwe, Malawi.Chris Hani Baragwanath Hospital. Perinatal HIV Research Unit. Soweto, South Africa.Statistical Center for HIV/AIDS Research and Prevention. Fred Hutchinson Cancer Research Center. Seattle, Washington, United States of America.Statistical Center for HIV/AIDS Research and Prevention. Fred Hutchinson Cancer Research Center. Seattle, Washington, United States of America.Johns Hopkins University. School of Medicine. Baltimore, Maryland, United States of America.Johns Hopkins University. School of Medicine. Baltimore, Maryland, United States of America.Johns Hopkins University. School of Medicine. Baltimore, Maryland, United States of America.Johns Hopkins University. School of Medicine. Baltimore, Maryland, United States of America.Johns Hopkins University. School of Medicine. Baltimore, Maryland, United States of America.FHI360. Durham, North Carolina, United States of America.Johns Hopkins University. Berman Institute of Bioethics. Baltimore, Maryland, United States of America./ Johns Hopkins University. School of Medicine. Baltimore, Maryland, United States of America.UCLA Center for Clinical AIDS Research and Education. Los Angeles, California, United States of America.National Institutes of Health. National Institute of Allergy and Infectious Diseases. Division of AIDS. Rockville, Maryland, United States of America.National Institutes of Health. National Institute of Allergy and Infectious Diseases. Division of AIDS. Rockville, Maryland, United States of America.ViiV Healthcare. Durham, North Carolina, United States of America.ViiV Healthcare. Durham, North Carolina, United States of America.ViiV Healthcare. Durham, North Carolina, United States of America.FHI360. Durham, North Carolina, United States of America.University of North Carolina at Chapel Hill. Chapel Hill, North Carolina, United States of America.Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral tablet for daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA]) for intramuscular (IM) administration, which delivers prolonged plasma exposure to the drug after IM injection. HIV Prevention Trials Network study 077 (HPTN 077) evaluated the safety, tolerability, and pharmacokinetics of CAB LA in HIV-uninfected males and females at 8 sites in Brazil, Malawi, South Africa, and the United States.CabotegravirHPTNHIV-uninfectedHIV treatmentHIV preventioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83099https://www.arca.fiocruz.br/bitstream/icict/30412/1/license.txt586c046dcfeef936e32f0323bb9a47c0MD51ORIGINALSafety, tolerability, and pharmacokinetics_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2018.pdfSafety, tolerability, and pharmacokinetics_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2018.pdfapplication/pdf3011719https://www.arca.fiocruz.br/bitstream/icict/30412/2/Safety%2c%20tolerability%2c%20and%20pharmacokinetics_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2018.pdf0a3064a705cc03d91997f42e8b04826fMD52TEXTSafety, tolerability, and pharmacokinetics_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2018.pdf.txtSafety, tolerability, and pharmacokinetics_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2018.pdf.txtExtracted texttext/plain71296https://www.arca.fiocruz.br/bitstream/icict/30412/3/Safety%2c%20tolerability%2c%20and%20pharmacokinetics_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2018.pdf.txtacad43614fc29bc393b514f12fd46fe8MD53icict/304122021-02-10 19:38:09.496oai:www.arca.fiocruz.br:icict/30412Q0VTU8ODTyBOw4NPIEVYQ0xVU0lWQSBERSBESVJFSVRPUyBBVVRPUkFJUw0KDQpGw6FiaW8gTWFycXVlcywgQ1BGOiAxMTMuMTg3Ljg1Ny00MCwgdmluY3VsYWRvIGEgSU5JIC0gSW5zdGl0dXRvIE5hY2lvbmFsIGRlIEluZmVjdG9sb2dpYSBFdmFuZHJvIENoYWdhcwoKQW8gYWNlaXRhciBvcyBURVJNT1MgZSBDT05EScOHw5VFUyBkZXN0YSBDRVNTw4NPLCBvIEFVVE9SIGUvb3UgVElUVUxBUiBkZSBkaXJlaXRvcwphdXRvcmFpcyBzb2JyZSBhIE9CUkEgZGUgcXVlIHRyYXRhIGVzdGUgZG9jdW1lbnRvOgoKKDEpIENFREUgZSBUUkFOU0ZFUkUsIHRvdGFsIGUgZ3JhdHVpdGFtZW50ZSwgw6AgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaLCBlbQpjYXLDoXRlciBwZXJtYW5lbnRlLCBpcnJldm9nw6F2ZWwgZSBOw4NPIEVYQ0xVU0lWTywgdG9kb3Mgb3MgZGlyZWl0b3MgcGF0cmltb25pYWlzIE7Dg08KQ09NRVJDSUFJUyBkZSB1dGlsaXphw6fDo28gZGEgT0JSQSBhcnTDrXN0aWNhIGUvb3UgY2llbnTDrWZpY2EgaW5kaWNhZGEgYWNpbWEsIGluY2x1c2l2ZSBvcyBkaXJlaXRvcwpkZSB2b3ogZSBpbWFnZW0gdmluY3VsYWRvcyDDoCBPQlJBLCBkdXJhbnRlIHRvZG8gbyBwcmF6byBkZSBkdXJhw6fDo28gZG9zIGRpcmVpdG9zIGF1dG9yYWlzLCBlbQpxdWFscXVlciBpZGlvbWEgZSBlbSB0b2RvcyBvcyBwYcOtc2VzOwoKKDIpIEFDRUlUQSBxdWUgYSBjZXNzw6NvIHRvdGFsIG7Do28gZXhjbHVzaXZhLCBwZXJtYW5lbnRlIGUgaXJyZXZvZ8OhdmVsIGRvcyBkaXJlaXRvcyBhdXRvcmFpcwpwYXRyaW1vbmlhaXMgbsOjbyBjb21lcmNpYWlzIGRlIHV0aWxpemHDp8OjbyBkZSBxdWUgdHJhdGEgZXN0ZSBkb2N1bWVudG8gaW5jbHVpLCBleGVtcGxpZmljYXRpdmFtZW50ZSwKb3MgZGlyZWl0b3MgZGUgZGlzcG9uaWJpbGl6YcOnw6NvIGUgY29tdW5pY2HDp8OjbyBww7pibGljYSBkYSBPQlJBLCBlbSBxdWFscXVlciBtZWlvIG91IHZlw61jdWxvLAppbmNsdXNpdmUgZW0gUmVwb3NpdMOzcmlvcyBEaWdpdGFpcywgYmVtIGNvbW8gb3MgZGlyZWl0b3MgZGUgcmVwcm9kdcOnw6NvLCBleGliacOnw6NvLCBleGVjdcOnw6NvLApkZWNsYW1hw6fDo28sIHJlY2l0YcOnw6NvLCBleHBvc2nDp8OjbywgYXJxdWl2YW1lbnRvLCBpbmNsdXPDo28gZW0gYmFuY28gZGUgZGFkb3MsIHByZXNlcnZhw6fDo28sIGRpZnVzw6NvLApkaXN0cmlidWnDp8OjbywgZGl2dWxnYcOnw6NvLCBlbXByw6lzdGltbywgdHJhZHXDp8OjbywgZHVibGFnZW0sIGxlZ2VuZGFnZW0sIGluY2x1c8OjbyBlbSBub3ZhcyBvYnJhcyBvdQpjb2xldMOibmVhcywgcmV1dGlsaXphw6fDo28sIGVkacOnw6NvLCBwcm9kdcOnw6NvIGRlIG1hdGVyaWFsIGRpZMOhdGljbyBlIGN1cnNvcyBvdSBxdWFscXVlciBmb3JtYSBkZQp1dGlsaXphw6fDo28gbsOjbyBjb21lcmNpYWw7CgooMykgUkVDT05IRUNFIHF1ZSBhIGNlc3PDo28gYXF1aSBlc3BlY2lmaWNhZGEgY29uY2VkZSDDoCBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPCkNSVVogbyBkaXJlaXRvIGRlIGF1dG9yaXphciBxdWFscXVlciBwZXNzb2Eg4oCTIGbDrXNpY2Egb3UganVyw61kaWNhLCBww7pibGljYSBvdSBwcml2YWRhLCBuYWNpb25hbCBvdQplc3RyYW5nZWlyYSDigJMgYSBhY2Vzc2FyIGUgdXRpbGl6YXIgYW1wbGFtZW50ZSBhIE9CUkEsIHNlbSBleGNsdXNpdmlkYWRlLCBwYXJhIHF1YWlzcXVlcgpmaW5hbGlkYWRlcyBuw6NvIGNvbWVyY2lhaXM7CgooNCkgREVDTEFSQSBxdWUgYSBvYnJhIMOpIGNyaWHDp8OjbyBvcmlnaW5hbCBlIHF1ZSDDqSBvIHRpdHVsYXIgZG9zIGRpcmVpdG9zIGFxdWkgY2VkaWRvcyBlIGF1dG9yaXphZG9zLApyZXNwb25zYWJpbGl6YW5kby1zZSBpbnRlZ3JhbG1lbnRlIHBlbG8gY29udGXDumRvIGUgb3V0cm9zIGVsZW1lbnRvcyBxdWUgZmF6ZW0gcGFydGUgZGEgT0JSQSwKaW5jbHVzaXZlIG9zIGRpcmVpdG9zIGRlIHZveiBlIGltYWdlbSB2aW5jdWxhZG9zIMOgIE9CUkEsIG9icmlnYW5kby1zZSBhIGluZGVuaXphciB0ZXJjZWlyb3MgcG9yCmRhbm9zLCBiZW0gY29tbyBpbmRlbml6YXIgZSByZXNzYXJjaXIgYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVogZGUKZXZlbnR1YWlzIGRlc3Blc2FzIHF1ZSB2aWVyZW0gYSBzdXBvcnRhciwgZW0gcmF6w6NvIGRlIHF1YWxxdWVyIG9mZW5zYSBhIGRpcmVpdG9zIGF1dG9yYWlzIG91CmRpcmVpdG9zIGRlIHZveiBvdSBpbWFnZW0sIHByaW5jaXBhbG1lbnRlIG5vIHF1ZSBkaXogcmVzcGVpdG8gYSBwbMOhZ2lvIGUgdmlvbGHDp8O1ZXMgZGUgZGlyZWl0b3M7CgooNSkgQUZJUk1BIHF1ZSBjb25oZWNlIGEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTwpPU1dBTERPIENSVVogZSBhcyBkaXJldHJpemVzIHBhcmEgbyBmdW5jaW9uYW1lbnRvIGRvIHJlcG9zaXTDs3JpbyBpbnN0aXR1Y2lvbmFsIEFSQ0EuCgpBIFBvbMOtdGljYSBJbnN0aXR1Y2lvbmFsIGRlIEFjZXNzbyBBYmVydG8gZGEgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaIHJlc2VydmEKZXhjbHVzaXZhbWVudGUgYW8gQVVUT1Igb3MgZGlyZWl0b3MgbW9yYWlzIGUgb3MgdXNvcyBjb21lcmNpYWlzIHNvYnJlIGFzIG9icmFzIGRlIHN1YSBhdXRvcmlhCmUvb3UgdGl0dWxhcmlkYWRlLCBzZW5kbyBvcyB0ZXJjZWlyb3MgdXN1w6FyaW9zIHJlc3BvbnPDoXZlaXMgcGVsYSBhdHJpYnVpw6fDo28gZGUgYXV0b3JpYSBlIG1hbnV0ZW7Dp8OjbwpkYSBpbnRlZ3JpZGFkZSBkYSBPQlJBIGVtIHF1YWxxdWVyIHV0aWxpemHDp8Ojby4KCkEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVoKcmVzcGVpdGEgb3MgY29udHJhdG9zIGUgYWNvcmRvcyBwcmVleGlzdGVudGVzIGRvcyBBdXRvcmVzIGNvbSB0ZXJjZWlyb3MsIGNhYmVuZG8gYW9zIEF1dG9yZXMKaW5mb3JtYXIgw6AgSW5zdGl0dWnDp8OjbyBhcyBjb25kacOnw7VlcyBlIG91dHJhcyByZXN0cmnDp8O1ZXMgaW1wb3N0YXMgcG9yIGVzdGVzIGluc3RydW1lbnRvcy4KRepositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352021-02-10T22:38:09Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial |
| title |
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial |
| spellingShingle |
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial Landovitz, Raphael J Cabotegravir HPTN HIV-uninfected HIV treatment HIV prevention |
| title_short |
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial |
| title_full |
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial |
| title_fullStr |
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial |
| title_full_unstemmed |
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial |
| title_sort |
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial |
| author |
Landovitz, Raphael J |
| author_facet |
Landovitz, Raphael J Li, Sue Grinsztejn, Beatriz Dawood, Halima Liu, Albert Y Magnus, Manya Hosseinipour, Mina C Panchia, Ravindre Cottle, Leslie Chau, Gordon Richardson, Paul Marzinke, Mark A Hendrix, Craig W Eshleman, Susan H Zhang, Yinfeng Tolley, Elizabeth Sugarman, Jeremy Kofron, Ryan Adeyeye, Adeola Burns, David Rinehart, Alex R Margolis, David Spreen, William R Cohen, Myron S McCauley, Marybeth Eron, Joseph J |
| author_role |
author |
| author2 |
Li, Sue Grinsztejn, Beatriz Dawood, Halima Liu, Albert Y Magnus, Manya Hosseinipour, Mina C Panchia, Ravindre Cottle, Leslie Chau, Gordon Richardson, Paul Marzinke, Mark A Hendrix, Craig W Eshleman, Susan H Zhang, Yinfeng Tolley, Elizabeth Sugarman, Jeremy Kofron, Ryan Adeyeye, Adeola Burns, David Rinehart, Alex R Margolis, David Spreen, William R Cohen, Myron S McCauley, Marybeth Eron, Joseph J |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Landovitz, Raphael J Li, Sue Grinsztejn, Beatriz Dawood, Halima Liu, Albert Y Magnus, Manya Hosseinipour, Mina C Panchia, Ravindre Cottle, Leslie Chau, Gordon Richardson, Paul Marzinke, Mark A Hendrix, Craig W Eshleman, Susan H Zhang, Yinfeng Tolley, Elizabeth Sugarman, Jeremy Kofron, Ryan Adeyeye, Adeola Burns, David Rinehart, Alex R Margolis, David Spreen, William R Cohen, Myron S McCauley, Marybeth Eron, Joseph J |
| dc.subject.en.pt_BR.fl_str_mv |
Cabotegravir HPTN HIV-uninfected HIV treatment HIV prevention |
| topic |
Cabotegravir HPTN HIV-uninfected HIV treatment HIV prevention |
| description |
2019-12-08 |
| publishDate |
2018 |
| dc.date.accessioned.fl_str_mv |
2018-12-05T18:04:24Z |
| dc.date.available.fl_str_mv |
2018-12-05T18:04:24Z |
| dc.date.issued.fl_str_mv |
2018 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
LANDOVITZ, R. J. et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS medicine, v. 15, n. 11, p. e1002690, 2018. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/30412 |
| dc.identifier.issn.pt_BR.fl_str_mv |
1549-1277 |
| dc.identifier.doi.none.fl_str_mv |
10.1371/journal.pmed.1002690 |
| identifier_str_mv |
LANDOVITZ, R. J. et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS medicine, v. 15, n. 11, p. e1002690, 2018. 1549-1277 10.1371/journal.pmed.1002690 |
| url |
https://www.arca.fiocruz.br/handle/icict/30412 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Public Library of Science |
| publisher.none.fl_str_mv |
Public Library of Science |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/30412/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/30412/2/Safety%2c%20tolerability%2c%20and%20pharmacokinetics_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2018.pdf https://www.arca.fiocruz.br/bitstream/icict/30412/3/Safety%2c%20tolerability%2c%20and%20pharmacokinetics_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2018.pdf.txt |
| bitstream.checksum.fl_str_mv |
586c046dcfeef936e32f0323bb9a47c0 0a3064a705cc03d91997f42e8b04826f acad43614fc29bc393b514f12fd46fe8 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813009261120192512 |